Ibrance Tablet, Film Coated
Product Images NDC 63539-486

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Ibrance (NDC 63539-486). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Ibrance 01)

Chemical structure diagram of palbociclib, the active ingredient in Ibrance tablets. The structure shows the arrangement of chemical rings and functional groups characteristic of palbociclib.*

FDA Label Image

Figure 1 (Ibrance 02)

A Kaplan-Meier curve showing progression-free survival probability over time in months, comparing palbociclib plus letrozole versus placebo plus letrozole. The graph includes patient numbers at risk at various time points for each treatment group.*

FDA Label Image

Figure 2 (Ibrance 03)

A Kaplan-Meier curve showing progression-free survival probability over time (months) comparing treatment with palbociclib plus fulvestrant versus placebo plus fulvestrant. The plot includes survival probability percentages on the vertical axis, time in months on the horizontal axis, and number of patients at risk at various time points for each group.*

FDA Label Image

Figure 3 (Ibrance 04)

A Kaplan-Meier overall survival probability graph comparing treatments of palbociclib plus fulvestrant versus placebo plus fulvestrant. The x-axis shows time in months (0-54), and the y-axis shows overall survival probability percentage (0-100%). The chart includes the number of patients at risk over time for each treatment group.*

FDA Label Image

Logo (Ibrance 05)

FDA Label Image

Logo (Ibrance 06)

FDA Label Image

Principal Display Panel (75 mg Tablet Dose Pack)

Ibrance 75 mg film-coated tablets packaging label by U.S. Pharmaceuticals. The weekly blister pack contains 7 tablets of palbociclib with instructions to take 1 tablet once daily for 21 consecutive days followed by 7 days off treatment. Storage directions and manufacturer details are included. The label states it is a professional sample and not for sale.*

FDA Label Image

Principal Display Panel (75 mg Tablet Dose Pack Box)

Packaging label for IBRANCE (palbociclib) tablets 75 mg by U.S. Pharmaceuticals. The label identifies the product as a professional sample, not for sale, containing 21 tablets in a monthly box with three weekly packs. The label includes storage instructions and dosage information with Pfizer branding visible.*

FDA Label Image

Principal Display Panel (100 mg Tablet Dose Pack)

Ibrance 100 mg film-coated tablets packaging label by U.S. Pharmaceuticals (Pfizer). The label indicates the product contains palbociclib with dosing instructions to take 1 tablet daily for 21 days followed by 7 days off treatment. The pack holds 7 tablets in a blister and includes storage instructions and professional sample notice.*

FDA Label Image

Principal Display Panel (100 mg Tablet Dose Pack Box)

Flat carton packaging for IBRANCE (palbociclib) film-coated tablets, 100 mg strength, labeled for 21 tablets total. The box is primarily white with purple accents and includes the Pfizer logo. The label notes the product is a professional sample and prescription only, distributed by U.S. Pharmaceuticals. Storage instructions and dosage details appear on the sides.*

FDA Label Image

Principal Display Panel (125 mg Tablet Dose Pack)

Ibrance 125 mg film-coated tablets packaging label. The label shows the brand and generic name palbociclib, dosage form as tablets, and strength of 125 mg per tablet. The package contains a weekly pack of 7 tablets. It includes usage instructions stating to take 1 tablet daily for 21 consecutive days followed by 7 days off treatment. The labeler is U.S. Pharmaceuticals, Pfizer Inc.*

FDA Label Image

Principal Display Panel (125 mg Tablet Dose Pack Box)

Flat carton packaging for Ibrance (palbociclib) tablets, 125 mg strength, labeled for 21 tablets. The design features the Pfizer logo and indicates a monthly box containing three individual weekly packs. The label states 'Professional Sample - Not for Sale' and includes storage instructions and distributor information for U.S. Pharmaceuticals. The carton has a white and green color scheme with clear dosage and product name on the front.*

FDA Label Image

Principal Display Panel (Topper Card)

An illustration titled 'Your Monthly Box' showing a treatment cycle tracker for Ibrance (palbociclib) medication. It indicates a cycle of 3 weekly packs labeled Week 1, Week 2, and Week 3 with Ibrance, and Week 4 marked as 'No Ibrance.' Below, a section titled 'My Treatment Cycle Tracker' includes blank fields to record the start date of Week 1 and the start date of the next treatment cycle after Week 4.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.